Ergonovine Side Effects
Medically reviewed by Drugs.com. Last updated on Sep 13, 2023.
Applies to ergonovine: compounding powder, injectable solution, oral tablet.
General
Administration of correct dose to carefully selected patients who are closely monitored, yields little risk of serious adverse systemic effects; however, IV administration may produce serious adverse effects if the injections are not diluted and administered slowly.[Ref]
Cardiovascular
Frequency not reported: Gangrene, coronary artery vasospasm, peripheral vasospasm, hypotension, hypertension, thrombophlebitis, myocardial infarction (single case report), ventricular arrhythmias, transient chest pain, palpitation, bradycardia, vasoconstriction
Gastrointestinal
Very rare (less than 0.01%): Mesenteric ischemia and large bowel infarction (single case report)
Frequency not reported: Abdominal pain, diarrhea, nausea, esophageal spasm, vomiting, unpleasant taste
Hypersensitivity
Frequency not reported: Allergic phenomena (including shock, hypertension, chest pain, palpitation, dyspnea, and bradycardia), anaphylactic/anaphylactoid reaction
Nervous system
Frequency not reported: Dizziness, headache
Metabolic
Frequency not reported: Clinical exacerbations of porphyria, water intoxication
Dermatologic
Frequency not reported: Sweating, diaphoresis, skin rashes
Respiratory
Frequency not reported: Dyspnea, nasal congestion, pulmonary edema, pleural thickening
Musculoskeletal
Very rare (less than 0.01%): Unmasking of myasthenia gravis (single case report)
Frequency not reported: Leg cramps
Postmarketing reports: Muscle spasm
Ocular
Postmarketing reports: Eye movement disorder
Psychiatric
Frequency not reported: Hallucinations
Genitourinary
Frequency not reported: Hematuria
Hepatic
Frequency not reported: Abnormal liver function test
Other
Frequency not reported: Vertigo, tinnitus
Renal
Postmarketing reports: Increased blood creatine
More about ergonovine
- Check interactions
- Compare alternatives
- Dosage information
- During pregnancy
- Drug class: uterotonic agents
- Breastfeeding
Patient resources
Related treatment guides
References
1. Cerner Multum, Inc. UK Summary of Product Characteristics.
2. Cerner Multum, Inc. Canadian Product Information. 2015.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.